Advancements and Obstacles of CRISPR-Cas9 Technology in Translational Research: Molecular Therapy - Methods & Clinical Development
Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia | NEJM
Editas Early Data for CRISPR Therapy EDIT-101 Shows Efficacy "Signals" in Two Patients
Frontiers | CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future | Oncology
Gene Editing
Clinical Data from Editas Medicine's Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the
Amid The Turmoil Of 2020, This Company Was The First To Treat Patients With A Genome Editing Therapy
In vitro validation of EDIT-101 a, Schematic representation of... | Download Scientific Diagram
Delivery technologies for T cell gene editing: Applications in cancer immunotherapy - eBioMedicine
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia | NEJM
Editas Medicine Stock | EDIT-101 Data SOON - Here's What to Expect! - YouTube
Editas' CRISPR asset make strides after positive eye disease trial
Research and Pipeline | Editas Medicine
Allergan and Editas Medicine Announce Dosing of First
Editas Medicine doses first pediatric patient in clinical trial for LCA10
Editas Medicine (@editasmed) / Twitter
JPM 2022: Editas, which caught flak in 2021 for limited gene editing data, will try to layer on the proof in 2022 | Fierce Biotech
Editas Medicine Announces Enrollment of the First Pediatric
News: Clinical Update: First Child Dosed in CRISPR Trial for Hereditary Blindness - CRISPR Medicine
News: CRISPR clinical trials overview 2020 - CRISPR Medicine
